Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PTGX

Protagonist Therapeutics Inc

Dec 13 • 04:00PM ET

41.08

Dollar change +0.70
Percentage change 1.73	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR VTI CALF IWM VXF XBI AVUV SPSM IWO IJT

Scroll to Statements

Index	RUT	P/E	15.41	EPS (ttm)	2.67	Insider Own	5.48%	Shs Outstand	59.52M	Perf Week	-2.33%
Market Cap	2.49B	Forward P/E	-	EPS next Y	-1.50	Insider Trans	-8.06%	Shs Float	56.33M	Perf Month	-3.73%
Income	170.85M	PEG	-	EPS next Q	0.13	Inst Own	100.44%	Short Float	6.04%	Perf Quarter	-11.08%
Sales	323.80M	P/S	7.69	EPS this Y	276.00%	Inst Trans	6.31%	Short Ratio	4.93	Perf Half Y	23.03%
Book/sh	8.94	P/B	4.60	EPS next Y	-161.35%	ROA	36.59%	Short Interest	3.40M	Perf Year	101.87%
Cash/sh	7.73	P/C	5.31	EPS next 5Y	-	ROE	40.97%	52W Range	19.16 - 48.89	Perf YTD	79.15%
Dividend Est.	-	P/FCF	10.87	EPS past 5Y	4.38%	ROI	31.48%	52W High	-15.97%	Beta	2.20
Dividend TTM	-	Quick Ratio	10.70	Sales past 5Y	2462.45%	Gross Margin	99.01%	52W Low	114.41%	ATR (14)	2.21
Dividend Ex-Date	-	Current Ratio	10.70	EPS Y/Y TTM	207.96%	Oper. Margin	46.05%	RSI (14)	43.81	Volatility	4.70% 6.12%
Employees	112	Debt/Eq	0.02	Sales Y/Y TTM	36565.08%	Profit Margin	52.76%	Recom	1.18	Target Price	58.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	6.70%	Payout	-	Rel Volume	0.77	Prev Close	40.38
Sales Surprise	50.20%	EPS Surprise	6.49%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	689.53K	Price	41.08
SMA20	-2.35%	SMA50	-7.43%	SMA200	11.42%	Trades		Volume	530,557	Change	1.73%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23

Show Previous Ratings

Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
04:30PM	Loading…
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
07:30AM	Loading…
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
08:20AM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-01-24 08:00AM	RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
07:00AM	Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
Jul-31-24 09:15AM	Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor (ACCESSWIRE)
Jul-22-24 07:00AM	Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 (ACCESSWIRE)
Jul-18-24 08:50AM	Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-11-24 06:00AM	3 Growth Stocks No One Is Watching (But They Should Be) (InvestorPlace)
Jun-28-24 04:07PM	Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 (Investor's Business Daily) +8.69%
12:11PM	Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024 (Associated Press)
Jun-27-24 05:44PM	Protagonist Therapeutics Set to Join S&P SmallCap 600 (PR Newswire)
01:43PM	Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy? (Insider Monkey)
10:12PM	Loading…
Jun-26-24 10:12PM	10 Best Healthcare Stocks to Buy Under $50 (Insider Monkey)
Jun-14-24 03:00AM	Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control (ACCESSWIRE)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace) +16.10%
May-31-24 07:30AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 (ACCESSWIRE)
May-14-24 04:05PM	Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress (ACCESSWIRE) +6.28%
May-07-24 11:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.12%
09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)
04:23PM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event (ACCESSWIRE)
04:05PM	Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +8.05%
04:05PM	Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
09:05AM	Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting (ACCESSWIRE)
Nov-01-23 04:05PM	Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis (ACCESSWIRE)
07:30AM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Oct-30-23 04:05PM	Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors (ACCESSWIRE)
Oct-09-23 07:00AM	Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications (ACCESSWIRE)
Oct-03-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Sep-05-23 07:30AM	Protagonist Therapeutics to Present at Upcoming Investor Conferences (ACCESSWIRE)
Aug-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Aug-09-23 07:00AM	Protagonist Receives $34 Million from Warrant Exercises (ACCESSWIRE)
Aug-03-23 04:48PM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Jul-18-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Award (ACCESSWIRE)
Jul-05-23 09:33AM	Protagonist Therapeutics-Janssen Partnered Psoriasis Candidate Fall Short Of Rival Treatment (Benzinga)
Jul-04-23 03:30AM	Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis (ACCESSWIRE)
Jun-30-23 08:50AM	Protagonist Therapeutics (PTGX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-15-23 09:55AM	Wall Street Analysts Predict a 25.35% Upside in Protagonist Therapeutics (PTGX): Here's What You Should Know (Zacks)
Jun-13-23 08:50AM	Here's Why Momentum in Protagonist Therapeutics (PTGX) Should Keep going (Zacks)
Jun-09-23 08:05AM	Clinical Response and Durability of Response of Rusfertide (PTG-300) in Polycythemia Vera Featured Today at EHA Press Briefing; Protagonist Therapeutics Plans a Follow-on Two-Year Extension Study to Enable Further Evaluation of the Long-Term Effects of Rusfertide in PV (ACCESSWIRE)
Jun-06-23 07:30AM	Protagonist Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at 2023 European Hematology Association (EHA) Congress (ACCESSWIRE)
Jun-01-23 04:01PM	Protagonist Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (ACCESSWIRE) +5.45%
May-26-23 09:55AM	How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 38.01% (Zacks)
May-12-23 03:14PM	Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment (Benzinga)
07:00AM	Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 (PR Newswire)
May-11-23 04:05PM	Protagonist Therapeutics to Participate in the JMP Securities Life Sciences Conference (PR Newswire)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Option Exercise	8.04	26,000	209,040	62,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Option Exercise	8.04	5,529	44,453	51,973	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Sale	44.70	26,000	1,162,280	46,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Sale	45.60	5,529	252,122	46,444	Nov 27 07:11 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Option Exercise	7.75	175,000	1,356,000	359,611	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Option Exercise	12.17	30,450	370,576	286,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Sale	46.04	103,437	4,762,239	256,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Sale	45.50	19,191	873,190	266,983	Nov 27 07:09 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Option Exercise	21.58	1,727	37,269	429,935	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Sale	46.96	78,520	3,687,299	435,208	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 26 '24	Sale	46.25	21,480	993,450	408,455	Nov 27 07:08 PM
MOLINA ARTURO MD	Officer	Nov 27 '24	Proposed Sale	44.00	16,000	704,000		Nov 27 04:39 PM
MOLINA ARTURO MD	Officer	Nov 26 '24	Proposed Sale	45.00	16,000	720,000		Nov 26 07:39 PM
Gupta Suneel	Officer	Nov 26 '24	Proposed Sale	45.50	19,191	873,184		Nov 26 07:37 PM
Gupta Suneel	Officer	Nov 25 '24	Proposed Sale	46.46	103,437	4,805,683		Nov 25 05:40 PM
Dinesh Patel	CEO	Nov 25 '24	Proposed Sale	45.93	100,000	4,593,000		Nov 25 04:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '24	Sale	40.98	1,906	78,108	46,444	Nov 19 06:49 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Option Exercise	15.68	12,000	188,160	46,960	Sep 13 04:35 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Sale	44.49	14,203	631,872	34,960	Sep 13 04:35 PM
Waddill William D.	Director	Sep 10 '24	Option Exercise	12.88	8,000	103,040	20,000	Sep 12 07:38 PM
Waddill William D.	Director	Sep 10 '24	Sale	45.00	8,000	360,000	12,000	Sep 12 07:38 PM
Ali Asif	Officer	Sep 11 '24	Proposed Sale	44.49	14,203	631,855		Sep 11 06:15 PM
WILLIAM D WADDILL	Director	Sep 10 '24	Proposed Sale	45.00	8,000	360,000		Sep 10 04:17 PM
Waddill William D.	Director	Jul 24 '24	Option Exercise	12.88	8,000	103,040	20,000	Jul 26 04:31 PM
Waddill William D.	Director	Jul 24 '24	Sale	40.00	8,000	320,000	12,000	Jul 26 04:31 PM
Waddill William D.	Director	Jun 07 '24	Option Exercise	12.88	8,000	103,040	20,000	Jun 11 04:30 PM
Waddill William D.	Director	Jun 07 '24	Sale	35.00	8,000	280,000	12,000	Jun 11 04:30 PM
PATEL DINESH V PH D	President and CEO	Jun 07 '24	Sale	35.19	35,000	1,231,650	515,415	Jun 11 04:30 PM
Ali Asif	Chief Financial Officer	Apr 18 '24	Sale	25.11	1,234	30,986	37,163	Apr 19 08:05 PM
PATEL DINESH V PH D	President and CEO	Apr 01 '24	Sale	28.31	25,000	707,750	549,590	Apr 02 08:29 PM
SELICK HAROLD E	Director	Mar 07 '24	Option Exercise	1.89	6,490	12,266	27,996	Mar 11 08:00 PM
PATEL DINESH V PH D	President and CEO	Mar 01 '24	Sale	31.62	30,000	948,600	574,590	Mar 01 08:46 PM
Waddill William D.	Director	Mar 01 '24	Option Exercise	6.09	12,975	79,018	24,975	Mar 01 08:45 PM
Waddill William D.	Director	Mar 01 '24	Sale	31.34	12,975	406,636	12,000	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Option Exercise	12.17	12,000	146,040	52,645	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Mar 01 '24	Sale	32.24	14,248	459,318	38,397	Mar 01 08:45 PM
Ali Asif	Chief Financial Officer	Feb 29 '24	Sale	30.69	9,939	305,048	40,645	Mar 01 08:45 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Option Exercise	7.38	5,000	36,900	192,567	Jan 11 08:00 PM
Gupta Suneel	Chief Development Officer	Jan 09 '24	Sale	25.00	5,000	125,000	187,567	Jan 11 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTGX

Protagonist Therapeutics Inc

Upgrade your FINVIZ experience